Results 251 to 260 of about 82,508 (316)

Identification of a novel TGFB1 variant in a patient with Camurati-Engelmann disease responsive to alendronate. [PDF]

Rheumatology (Oxford)
Hassan N, Gregson CL, Oldridge M, Lester T, Duncan EL, Tobias JH.   +5 more
europepmc   +1 more source

Bone complications after hand and face transplantation: Mechanisms and management. [PDF]

JPRAS Open
Dirican O, Sazoglu B, Demir Z, Kodali NA, Janarthanan R, Kulahci Y, Zor F, Gorantla VS.   +7 more
europepmc   +1 more source

Msx‐1 is suppressed in bisphosphonate‐exposed jaw bone analysis of bone turnover‐related cell signalling after bisphosphonate treatment

, 2011
Falk Wehrhan, Peter Hyckel, Kerstin Amann, Jutta Ries, Paul T. Stockmann, K. A. Schlegel, FW Neukam, Emeka Nkenke   +7 more
openalex   +2 more sources

Beyond bone effects: the role of denosumab in muscle Health - A systematic review. [PDF]

Aging Clin Exp Res
Ceolin C, Ziliotto C, Papa MV, Bertocco A, Sergi G, De Rui M.   +5 more
europepmc   +1 more source

Bilateral Orocutaneous Fistulas and Mandibular Osteonecrosis

International Journal of Dermatology, Volume 65, Issue 2, Page 374-375, February 2026.
Krisztian Nemeth, Mollye Goldberg, Zachary Fridirici   +2 more
wiley   +1 more source

The relationship between osteoporosis treatment history and receipt of a second zoledronic acid dose. [PDF]

Osteoporos Int
Konstantelos N, Kim S, Cheung AM, Burden AM, Grootendorst P, Cadarette SM.   +5 more
europepmc   +1 more source

Synthesis of Amino-<i>gem</i>-Bisphosphonate Derivatives and Their Application as Synthons for the Preparation of Biorelevant Compounds. [PDF]

Pharmaceuticals (Basel)
Ordoñez M, Argüello Velasco RO.
europepmc   +1 more source

Pharmacist Awareness, Knowledge, and Clinical Engagement of Medication-Related Osteonecrosis of the Jaw: A Survey From a Designated Community Cancer Care Hospital. [PDF]

Cureus
Sano M, Iijima Y, Watanabe S, Sagara A, Ushikubo K, Yamada M, Ohya H, Morimoto M, Horie N, Kaneko T.   +9 more
europepmc   +1 more source

Real-life use of bone-targeting agents for bone metastases in France between 2009 and 2018: Results of the OPTIMOS study. [PDF]

J Bone Oncol
Confavreux CB, Bouvard B, Girard N, Bosco-Levy P, Marchal C, Nolin M, Lehmann E, Desameric G, Belhassen M.   +8 more
europepmc   +1 more source